Purpose: To determine the impact of using fiducial match for daily image-guidance on pelvic lymph node (PLN) coverage for prostate cancer patients receiving stereotactic body radiation therapy (SBRT). The dosimetric impact of the translational differences was calculated by shifting the plan isocenter.
compared with presimulation volume were essential for adequate coverage of PLN in a hypofractionated treatment regime.
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| INTRODUCTION
Radiotherapy (RT) is a commonly used modality for the treatment of prostate cancer. Patients with high-risk prostate cancer, which is defined by the National Comprehensive Cancer Network as having at least one adverse feature (T3a or higher; Gleason score 8-10, or prostate-specific antigen > 20 ng/mL), have an increased risk for nodal involvement. 1 Therefore, it is recommended that pelvic lymph nodes (PLN) be included in the target volume for those patients. In addition, there is evidence of clinical benefit from PLN treatment in the high-risk population. 2, 3 Given the low α/β ratio attributed to prostate cancer, (approximately 1.5-1.8), hypofractionation is potentially more beneficial for occult nodal metastases in high-risk patients. 4 At our institution, high-risk prostate patients with Gleason score > 8 are considered to undergo PLN external beam irradiation.
Because more accelerated courses of moderate and ultra-hypofractionation RT are currently being used for prostate treatments, evaluating the role of PLN treatment with hypofractionation continues.
The ongoing phase II SATURN trial (NCT01953055), assessing the toxicity and clinical outcomes of 500 cGy per fraction to pelvic nodes, has finished accrual; a report of the initial outcomes is expected in 2019. Several small, preliminary trials have been reported, evaluating the feasibility and safety of this approach. [5] [6] [7] [8] At our institution, hypofractionated PLN RT is done in specific cases, and the urinary and bowel toxicity of 21 patients treated with PLN hypofractionation was recently evaluated. At this point, with a median follow-up of 9 months, urinary and gastrointestinal toxicities were evaluated, which will be reported in a future study. Preliminary assessments indicate that stereotactic body radiation therapy (SBRT)
to PLNs given in five fractions (for a total dose of 25 Gy) using dose painting to the prostate and seminal vesicles is safe and well tolerated without increased rates of gastrointestinal toxicity. However, longer follow-up is required to assess the efficacy of this treatment as well as its effect on biochemical control.
It is well known that the PLN are relatively fixed with respect to the pelvic vasculature, or the nearby bony anatomy, and move independently of the prostate. This raises the question of adequacy of PLN coverage when the image-guided setup based on a prostate fiducial match is utilized for patients undergoing intensity modulated radiation therapy. This has been extensively studied for conventional fractionation, and it has been concluded that over a conventionally fractionated course of treatment, random shifts will provide adequate coverage that is unlikely to result in impactful underdosing. [9] [10] [11] [12] However, limited studies with small number of patients exist regarding pelvic node coverage using SBRT. 13 In this scenario, in addition to systematic errors, random errors may also have a large negative impact. 14 The purpose of this study was to assess PLN coverage based on prostate fiducial matching during daily SBRT treatment.
| MATERIALS AND METHODS
Thirty intact gland prostate patients who underwent five fraction SBRT treatment to the prostate and PLN from 2014-2016 were evaluated in this IRB-approved study. Each patient received either 800 cGy × 5 fx or 500 cGy × 5 fx to the prostate and 500 cGy × 5 fx to PLN. Pelvic CTV lymph node volumes were delineated up to aortic bifurcation by placing a 7 mm margin around the vessels, carving out bowel, bladder, and bone tissue, as per Radiation Therapy
Oncology Group genitourinary radiation oncology specialists consensus. 15 There are currently no guidelines for PLN hypofractionation, and the same margins around the vessels to generate clinical target volume (CTV) lymph nodes when moving from a conventional to a hypofractionation scenario have been used. Additionally, a 5 mm margin around the CTV was used to create the planning target volume (PTV) to account for day-to-day setup variation. Prostate CTV volume included entire prostate and bilateral seminal vesicles. A uniform 5 mm margin around the prostate CTV except a 3 mm margin at the prostate-rectal interface was used to create the prostate PTV.
All patients were treated on Varian TM linear accelerator and positioned using the on-board cone beam CTs (CBCT). were also evaluated by calculating pairwise correlation coefficients.
2.A | Simulation protocol
Coefficients with P < 0.05 were considered statistically significant.
The coefficient values and the strength of association was calculated using general guidelines provided by Cohen et al. 16 as shown in Table 1 .
2.C | Dosimetric analysis
Dose calculations on all treatment plans were performed using Analytical Anisotropic Algorithm (AAA) in Eclipse treatment planning system Version 13.6. Two to three 15 MV arcs using volumetric modulated arc therapy technique (VMAT) was utilized. During planning, optimization was performed to achieve PLN PTV D95 ≥ 90%
and PTV mean dose of 101%-103%. The dosimetric impact of the translational shifts on PLN coverage was evaluated by shifting the plan isocenter based on the translational shifts calculated between fiducial and bony match for each fraction. The beams were moved in the direction opposite to the direction of translational shift to simulate the patient shift. Once the beams were moved for each fraction on the planning CT, the dose was recalculated. The effect on CTV PLN D95 and CTV PLN V100 was evaluated. The dosimetric difference between planning and dose recalculation based on the translational shift was also calculated. between translational shifts and change in bladder volume was not statistically significant (see Table 2 
3.C | Dosimetric impact
Mean CTV PLN D95 on the planning scan was 100% (range: 88.8%-108% 47%-100%), respectively. Nine patients had average CTV PLN V100 < 90% for all five fractions. Poor dosimetric coverage was associated with larger translational shift. A pairwise correlation between translational shift and CTV PLN D95 and V100 showed a strong negative correlation with the AP translational shift (P < 0.0001) and strong positive correlation with the SI translational shift (P < 0.0001). (Table 4 ).
The dosimetric difference between planning and dose recalculation based on the translational shift was also calculated and correlated with the translational shifts. Similar to the absolute dose metric, change in dosimetric parameter also showed a strong negative correlation with the AP translational shift and strong positive correlation with the SI translational shift.
| DISCUSSION
In this study, we examined the effect of soft tissue-based daily image guidance on PLN coverage of prostate cancer patients undergoing SBRT. This is one of the first studies to evaluate 30 prostate patients undergoing SBRT with PLN irradiation and daily CBCTguided fiducial-based image guidance. Our data indicate that up to 75% of fractions were covered within 5 mm margin near the PLN when they were positioned daily based on fiducials in the prostate.
A 7 mm margin would cover approximately 90% of the patient population translational shifts along the SI and AP directions were more significant than those along the LR direction. Shifts up to 15 mm were seen in the SI and AP directions. Some of these larger shifts were due to large prostate rotations, or large variation in bladder and rectal volumes. The current analysis does not take into account the prostate rotation because this is not the current clinical practice at our institution.
In terms of dosimetric impact of these translational shifts, we found, on average,~19% of the fractions had CTV D95 coverage of <90% as a result of these shifts. One patient had CTV PLN D95 < 90% during planning as well as during all subsequent fractions. Excluding this patient,~16% of the fractions had CTV D95 coverage of <90% as a result of these shifts. PLN coverage based on prostate fiducial match for intermediate-to high-risk prostate cancer patients has been extensively studied for conventional fractionation. Hsu, et al. reported a <1.5% difference in dose delivered to the PLN for five patients with simulated random shifts, and a 10% difference in dose delivered to the PLN, modeling a 1 cm systematic displacement using a 5 mm planning margin around the lymph nodes. 10 Only one study looked at the dosimetric impact of PLN coverage in a SBRT setting based on 5 mm CTV-to-PTV margin. Kishen, et al. analyzed 12 patients (65 CBCT scans) undergoing SBRT with PLN irradiation and found the average V100 CTVN was 92.6%, but for a subset of three patients, the average was 80.0%, compared with 97.8% for the others [P < 0.0001]). 13 These patients had large bone-to-fiducial translational shifts and a large variation in bladder height (calculated on the anteriormost coronal plane). Six out of 30 patients in our study had an average CTV D95 < 90% (79%, 85%, 86%, 76%, 82%, 89%, respectively averaged over all five fractions). Eight patients including the six above had CTV PLN V100 < 90%. Three of these patients had their CTV PLN V100 < 90% in the reference treatment plan as well. Our study looked at changes in bladder volume and 
